KyungDong Pharm home
Prescription Medicines

Fenoba Tab.

Product Category
Hyperlipidemia treatment
Active Ingredients
Fenofibrate
Appearance
A white, oblong, film-coated tablet.
Reimbursement Code
648103470
View Regulatory Information on the MFDS Portal ↗
1. Composition and Strength : 1 tablet
- Active ingredient: Fenofibrate (BP) ---------- 160mg
- Additives (animal-derived ingredients): Lactose hydrate (cow, milk)
- Other additives: Glyceryl dibehenate, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, sodium starch glycolate, colloidal silicon dioxide, crospovidone, Tabshield White (11W001), Tabshield White (22W265), Poloxamer 188, Hypromellose 2910

2. Efficacy/Effectiveness
Primary hyperlipidemia:
Hypercholesterolemia (type IIa),
Combined type of hypercholesterolemia and hypertriglyceridemia (type IIb, type III),
Hypertriglyceridemia (type IV)

3. Usage/Dosage
○ Adults: fenofibrate, 160 mg orally once a day immediately after a meal.
○ Children: There is still no clinical data regarding the use of this drug in children.

Fenofibrate must be administered in conjunction with diet.
This medication may be less absorbed on an empty stomach, so administer it immediately after a meal.

○ Elderly: If renal function is not reduced, dose reduction is generally not necessary.
○ Patients with renal impairment: Do not administer this drug to patients with moderate to severe renal impairment (serum creatinine level 2.5 mg/dL or higher).

4. Precautions for use
1. Do not administer to the following patients.
1) Patients with liver impairment
2) Patients with moderate to severe renal impairment (serum creatinine level of 2.5 mg/dL or more) (rhabdomyolysis may occur.)
3) Pregnant women, women who may be pregnant, or lactating women
4) Patients with hypersensitivity to this drug or its components
5) Patients with pre-existing gallbladder disease (gallstone formation has been reported)
6) Patients who experienced photoallergy or phototoxicity during treatment with fibrates or ketoprofen
7) Pediatrics
8) Patients with biliary cirrhosis
9) Patients with pancreatitis (excluding acute pancreatitis due to severe hypertriglyceridemia)
10) Since this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
11) Patients who are hypersensitive to or have a history of allergy to soybean oil
12) Patients with hypersensitivity to soybeans or peanuts

2. Administer with caution to the following patients.
1) Patients with mild renal impairment or a history of it (serum creatinine level 1.5 mg/dL or more but less than 2.5 mg/dL) (Rhabdomyolysis may occur, so reduce the dose or extend the interval between doses.)
2) Patients with abnormalities in liver function tests or patients with a history of such abnormalities (abnormal fluctuations in liver function test values may occur).
3) Patients with hypoalbuminemia (nephrotic syndrome)
4) Patients with a history of gallstones (gallstone formation has been reported)
5) Patients taking blood coagulation inhibitors
6) Patients taking HMG-CoA reductase inhibitors (e.g. pravastatin, simvastatin, etc.)
7) Elderly people
8) Patients with fat metabolism abnormalities such as hyperlipidemia, diabetic hyperlipidemia, and pancreatitis, or patients who require careful administration of lipid emulsions

3. Adverse reactions
1) Hepatobiliary system: Occasionally, elevated serum aminotransferase levels, rarely hepatomegaly, and very rarely, cholestasis hepatitis and gallstones may occur.
2) Skin: Frequent rashes, itching, or photosensitivity reactions: Exposure to sunlight or artificial UV rays may cause skin photosensitivity reactions accompanied by erythema, vesicle formation, or skin nodules on some parts of the skin. In rare cases, hair loss may occur.
3) Nervous system: Asthenia, high temperature, frequent dizziness, headache, and rarely peripheral neuropathy may occur.
4) Vascular system: Sometimes thromboembolism (pulmonary embolism, deep vein thrombosis) may occur.
5) Musculoskeletal system: Occasionally, creatine kinase (CK) elevation (more than 5 times the normal value), muscle pain, and muscle cramps may occur, so in such cases, reduce the dose or stop taking the medication. In addition, in very rare cases, joint pain and rhabdomyolysis may occur in case of overdose. In particular, patients with renal dysfunction may experience rhabdomyolysis, which is characterized by muscle pain, weakness, elevated creatine kinase (CK), elevated myoglobin in the blood and urine, and accompanying rapid deterioration of renal function.
6) Hypersensitivity reaction: Phototoxicity and photosensitivity reactions such as urticaria and photosensitivity eczema may occur.
7) Digestive system: Frequent gastrointestinal disorders (abdominal pain, nausea, vomiting, diarrhea and abdominal bloating), and sometimes pancreatitis may occur.
8) Respiratory system: In very rare cases, interstitial lung abnormalities may occur.
9) Blood: In rare cases, hemoglobin decrease, white blood cell decrease, and very rarely eosinophilia may occur.
10) Kidney: Rarely, elevations of serum creatinine and urea may occur.
11) Others: Eosinophilic pneumonia, ventricular arrhythmia, frequent fatigue, rare sexual dysfunction, and very rarely weight gain may occur.

4. General precautions
1) Since rhabdomyolysis accompanied by rapid deterioration of renal function may occur in patients with renal impairment, the renal function of the patient receiving the drug should be examined to determine whether to administer it, and appropriate measures such as reducing the dose or extending the administration interval should be taken depending on the serum creatinine level.
2) Before administration, consider administration after conducting sufficient tests and confirming that you have hyperlipidemia.
3) Before administration, diet should be implemented and exercise therapy, high blood pressure, smoking, and other risk factors for ischemic heart disease should be carefully considered.
4) During administration, regularly check the blood lipid concentration (even after administration for about 3 months), and if the treatment effect is not recognized, administration is discontinued.
5) Liver function: Daily doses of 96 to 145 mg of this drug were associated with increases in serum transaminases (AST or ALT). In a pooled analysis of 10 placebo-controlled clinical trials, an increase greater than 3 times the upper limit of the normal range occurred in 5.3% of patients taking this drug and 1.1% of patients in the placebo group. When transaminase tests were subsequently performed after discontinuation of treatment or during continued treatment, they generally returned to the normal range. The incidence of transaminase increases associated with treatment with this drug appeared to be dose related. In an 8-week dose-ranging study, the incidence of ALT or AST elevations of at least 3 times the upper limit of the normal range was 13% in patients receiving doses of 96 to 145 mg per day of REFLEX, and the incidence was 0% in patients receiving placebo or 45 mg or less of REFLEX per day. Hepatocellular hepatitis, chronic active hepatitis, and cholestatic hepatitis associated with treatment with this drug have been reported several weeks to several years after administration of this drug. In extremely rare cases, cirrhosis associated with chronic active hepatitis has been reported. Because elevations in AST, ALT, γ-GTP, LDH, and ALP, jaundice, and hepatitis may occur, liver function tests are performed monthly until 3 months after starting treatment and every 3 months thereafter. If an abnormality is recognized, appropriate measures, such as reducing or discontinuing the intake, must be taken, and a liver function test must be performed within at least one month.
Meanwhile, if AST or ALT continues to exceed 2.5 times the upper normal limit or 100 IU, administration is discontinued.
6) Cholelithiasis: Like clofibrate and gemfibrozil, which can cause cholelithiasis, this drug may increase cholesterol excretion into bile. If cholelithiasis is suspected, gallbladder investigation should be performed. If gallstones are discovered, treatment with this drug should be discontinued.
7) Pancreatitis: Pancreatitis has been reported in patients taking fenofibrate, gemfibrozil, and clofibrate. This occurrence may be considered a failure of the drug's efficacy in patients with severe hypertriglyceridemia due to a direct drug effect or secondary events mediating gallstone or deposit formation accompanying common bile duct obstruction.
8) Hypersensitivity reactions: Acute hypersensitivity reactions, including rare cases of mucocutaneous ophthalmic syndrome (Stevens-Johnson syndrome) and occasional reports of toxic epidermal necrolysis (Riel syndrome), as well as skin rashes requiring hospitalization and steroid treatment, have occurred very rarely during treatment with this drug. In controlled clinical trials, urticaria occurred in 1.1% of patients receiving this drug compared to 0% in the placebo group, and rash occurred in 1.4% of patients receiving this drug compared to 0.8% of those receiving placebo.
· Acute hypersensitivity: Anaphylaxis and angioedema were reported in overseas post-marketing surveillance of fenofibrate. In some cases, hypersensitivity reactions were life-threatening and required emergency treatment. If a patient develops signs or symptoms of an acute hypersensitivity reaction, seek medical attention immediately and discontinue administration of this drug.
· Delayed hypersensitivity: Severe skin adverse reactions (SCAR), including severe DRESS syndrome, were reported in overseas post-marketing studies several days to several weeks after fenofibrate administration. DRESS cases were associated with a combination of skin reactions (e.g., exfoliative dermatitis) and eosinophilia, fever, and systemic organ involvement (kidney, liver, respiratory). If SCAR is suspected, this drug should be discontinued and appropriate treatment should be considered.
9) Hematological changes: Mild to moderate decreases in hemoglobin, hematocrit, and white blood cells were observed in patients who started fenofibrate treatment. However, these levels stabilize during long-term administration. Very rare cases of thrombocytopenia and agranulocytosis have been reported in post-marketing surveillance. Regular blood counts are recommended for the first 12 months of treatment.
10) Skeletal muscle: Using fibrates alone, including this drug, may cause myopathy. In general, treatment with fibrate drugs in patients with renal impairment may rarely result in rhabdomyolysis. Myopathy should be considered in patients with diffuse muscle pain, muscle tenderness or weakness, and/or significant elevations in creatine kinase (CK) levels. Patients should be encouraged to immediately report any unspecified muscle pain, tenderness, or weakness, especially if accompanied by malaise or fever. Patients who develop these symptoms should have their creatine kinase (CK) levels evaluated and treatment with this drug discontinued if a significant increase in creatine kinase (CK) levels occurs or if myopathy is diagnosed.
11) Venous thromboembolic disease: In the FIELD clinical trial, pulmonary embolism (PE) and deep vein thrombosis (DVT) were observed at a higher incidence in the drug treatment group than in the placebo group.
12) Serum creatinine: An increase in serum creatinine has been reported. These increases return to baseline after discontinuation of treatment with this drug. The clinical significance of these observations has not been confirmed.
13) It is recommended to check plasma lipid levels when administering this drug to patients expected to be at special risk due to fat overload. If the external excretion of fat is judged to be insufficient through this inspection, the administration of this drug should be adjusted appropriately. If the patient is simultaneously receiving other intravenous lipid medications, the dosage of the lipid medication should be reduced considering the amount of lipids mixed as excipients in this drug.

5. Interaction
1) In the absence of pharmacokinetic interaction, the concomitant use of fibric acid derivatives and HMG-CoA reductase inhibitors has been reported in numerous cases of rhabdomyolysis, significantly elevated creatine kinase (CK) levels, and myoglobinuria, which is a high cause of acute renal failure. Therefore, caution should be exercised as the possibility of rhabdomyolysis may increase when administered in combination with HMG-CoA reductase inhibitors (lovastatin, etc.). If possible, it is advisable to avoid co-administration.
2) Combined use with oral anticoagulants: Because it enhances coumarin-type anticoagulants and prolongs prothrombin time/INR, caution should be exercised when using this drug together with oral anticoagulants. The dose of anticoagulants should be reduced to maintain the prothrombin time/INR required to prevent bleeding complications. Frequent prothrombin time/INR measurements are recommended until the prothrombin time/INR stabilizes.
3) Sulfonylurea hypoglycemic agents (e.g., glibenclamide, glimepiride, etc.): There have been reports of hypoglycemia (cold sweat, strong hunger, palpitations, etc.), and when used together, the blood sugar level and patient's condition must be carefully observed before administration.
4) Since this drug has a uric acid excretion effect, when administered in combination with uric acid treatment drugs, administer with caution, including adjusting the dosage.
5) Oral contraceptives (estrogen products) may increase blood lipid concentration, so consult a doctor when taking this drug together.
6) Do not co-administer with drugs with a risk of hepatotoxicity such as perhexiline hydrogen maleate and MAO inhibitors.
7) Cyclosporine: Cyclosporine may cause nephrotoxicity by decreasing creatinine clearance and increasing serum creatinine, and because the primary excretion route for fibrate drugs, including this drug, is the kidneys, there is a risk of worsening interactions. When coadministering this drug with immunosuppressants and other potentially nephrotoxic drugs, the benefits and risks should be carefully considered, and the lowest effective dose should be applied. In organ transplant patients undergoing immunosuppressive therapy, reversible renal function impairment accompanied by an increase in serum creatinine level has been reported in rare cases when this drug is administered together. Therefore, in such cases, renal function should be closely observed and administration should be discontinued if abnormalities are confirmed in laboratory test results.
8) Resin: Since bile acid binding resin can bind to other drugs administered simultaneously, this drug should be taken at least 1 hour before or 4 to 6 hours after taking bile acid binding resin to avoid interference with absorption.

6. Administration to pregnant and lactating women
1) When administered during pregnancy (especially after 3 months of pregnancy), there is a risk of accumulation in the fetus and causing fetal toxicity, so do not administer to pregnant women or women who may be pregnant.
2) Avoid administration during lactation as it is not known to pass into breast milk (there are reports that it passes into breast milk in rats).

7. Administration to children
This drug is not administered to children.

8. Administration to elderly people
1) In general, elderly people often have reduced liver and kidney function, tend to have low body weight, etc., so they are prone to adverse reactions, so administer with caution. In particular, serum creatinine levels should be checked regularly during treatment for renal function.
2) Be careful because there have been reports of hypoglycemia (cold sweat, strong hunger, palpitations, etc.) in the elderly due to combined use with sulfonylurea hypoglycemic agents (glibenclamide, etc.).

9. Treatment in case of overdose
No cases of overdose have been reported. There is no known antidote. Symptoms of overdose of this drug are unclear. Because this drug has a high protein binding rate, it is not removed by hemodialysis.

10. Precautions for storage and handling
1) Keep out of reach of children.
2) Be careful because changing it into another container may cause an accident or is undesirable in terms of maintaining quality.

11. Others
The occurrence of liver tumors has been reported during long-term administration to rodents.

5. How to save
Airtight container, stored at room temperature (1~30℃)

6. Packaging unit
100 tablets (10 tablets/PTPX10)

7. Period of use
24 months from date of manufacture

Product Updates

Total 1items

No.Product NameDetailsDate of ChangeDownload
1Fenoba Tab.Precautions for use2019.04.11PDF0010_201404451_Precautions for use (Fenova tablets).pdf